A Randomized, Multicenter, Double-Blind, Study to Evaluate the Efficacy of Tirofiban HCl Versus Placebo in the Setting of Standard Therapies Among Subjects Undergoing Percutaneous Coronary Intervention.
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Tirofiban (Primary)
- Indications Coronary artery disease; Thrombosis
- Focus Therapeutic Use
- Acronyms ATLAST-PCI
- Sponsors Medicure
- 09 Mar 2018 Status changed from suspended to withdrawn prior to enrolment.
- 18 Jan 2012 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.
- 26 Sep 2011 Planned initiation date changed from 1 May 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.